These preclinical data serve as proof-of-concept for synthetic lethality in BRCA-deficient cell lines and provide important rationale for studying PARP inhibitors in patients with BRCA1/2-asssociated breast and ovarian cancer. Here, BRCA1 is linked to ovarian cancer.